2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppression
2013
Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia
Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: Implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug And Alcohol Dependence 2013, 132: 378-382. PMID: 23414931, PMCID: PMC3718876, DOI: 10.1016/j.drugalcdep.2013.01.005.Peer-Reviewed Original ResearchConceptsMethadone maintenance treatmentMethadone doseKaplan-Meier survival analysisDose escalation procedureMethadone initiationThirty HIVMMT clinicsEvaluable participantsMaintenance treatmentOpioid dependenceMMT programSide effectsHigh dosesSurvival analysisHIVFirst weekPilot studyDoseMonthsTreatmentEscalation procedureDosesCravingParticipantsMonths of release